Clinical trial · Interventional
Proteiomic Fingerprints of Gastric Juice
Diagnosis of Gastroduodenal Diseases by Proteiomic Fingerprints of Gastric Juice
NCT00834236CI-TRIAL-00020087completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gastric cancer | Other | — | UNRESOLVED |
| normal subject | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- gastric cancer
- description
- gastric cancer patients
- interventionNames
- Other: normal subject
- Other: gastric cancer
- type
- ACTIVE_COMPARATOR
- label
- normal subject
- description
- healthy subject
- interventionNames
- Other: normal subject
- Other: gastric cancer
Primary outcomes (1)
- measure
- Number of Participants With Accurate Diagnosis for Gastric Cancer
- timeFrame
- 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * healthy subjects and gastric cancer patients documented by endoscopy. Exclusion Criteria: * the use of proton pump inhibitors or histamine-2 receptor antagonists within 4 weeks prior to the study * coexistence of two kinds of gastroduodenal lesions * coexistence of severe systemic diseases
References
Publications (0)
Data not yet available
No reference posted for this study.